Skip to main content
SpringerLink
Log in

Use of Nesiritide in the Management Algorithm of Acute Decompensated Heart Failure

  • Chapter
Acute Heart Failure

  • 2402 Accesses

Abstract

Acute decompensated heart failure (ADHF) is an emerging component of heart failure that is incompletely understood, lacks clear pathophysiologic mechanisms, is associated with worrisome outcomes, and is confounded by only minimally effective treatment options. Currently, treatment is targeted toward abnormal hemodynamics and includes diuretics, vasodilators, and inotropes. Nesiritide (B-type natriuretic peptide), represents a novel therapeutic option for ADHF that lowers elevated filling pressures and improves dyspnea. However, the risk/benefit ratio represents an unresolved issue, as important questions persist regarding drug-related morbidity and mortality. More research is needed to address safety, identify the ideal clinical scenario, and to resolve the absence or presence of drug associated risks.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2005;(158):1–199.

    Google Scholar 

  2. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26;(4):384–416.

    Article  PubMed  Google Scholar 

  3. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a populationbased study. Arch Intern Med 2002;162:1689–94.

    Article  PubMed  Google Scholar 

  4. Adams KF, et al. Heart Failure Society of America Guideline Writing Committee. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006;12:10–38.

    Article  Google Scholar 

  5. Fonarow GC, for the ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(suppl 7):S21–30.

    PubMed  Google Scholar 

  6. The ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294:1625–33.

    Article  Google Scholar 

  7. Emerman CL, DeMarco T, Costanzo MR, Peacock WF, for the ADHERE® Scientific Advisory Committee. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE® Registry (abstract 368). J Card Fail 2004;10(suppl 4):S116.

    Article  Google Scholar 

  8. Ikram H, Chan W, Espiner EA, et al. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci 1980;59(6):443–9.

    CAS  PubMed  Google Scholar 

  9. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105(11):1348–53.

    Article  CAS  PubMed  Google Scholar 

  10. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103(1):1–6.

    CAS  PubMed  Google Scholar 

  11. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 2003;42(4):705–8.

    Article  CAS  PubMed  Google Scholar 

  12. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100(12):1311–5.

    CAS  PubMed  Google Scholar 

  13. Ellison, DH. Diuretic drugs and the treatment of edema from clinic to bench and back again. Am J Kidney Dis 1994;23(5):623–43.

    CAS  PubMed  Google Scholar 

  14. Costanzo MR, for UNLOAD: Ultrafiltration vs. IV Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure. Late Breaking Clinical Trials. ACC Scientific Meeting March 14, 2006, Atlanta, Georgia.

    Google Scholar 

  15. Cuffe, MS, Califf RM, Adams KF, et al., OPTIMECHF. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure). Short-term intravenous milrinone for acute exacerbation of chronic heart failure. A randomized controlled trial. JAMA 2002;287:1541–7.

    Article  CAS  PubMed  Google Scholar 

  16. Stiles S. SURVIVE: no levosimendan survival benefit over dobutamine in acute HF. http://www.theheart.org.

    Google Scholar 

  17. Stiles S. REVIVE-2: levosimendan improves five-day clinical status in acute HF. http://www.theheart.org.

    Google Scholar 

  18. Abraham WT, Adams KF, Fonarow GC, et al., the ADHERE Scientific Advisory Committee and Investigators and the ADHERE Study Group. Inhospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46(1):57–64.

    Article  PubMed  Google Scholar 

  19. Ferreira A, Bettencourt P, Dias P, et al. Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clin Sci 2001;100(5):557–66.

    Article  CAS  PubMed  Google Scholar 

  20. Keating GM, Goa KL. Nesiritide: a review of its use in acute decompensated heart failure. Drugs 2003;63(1):47–70.

    Article  CAS  PubMed  Google Scholar 

  21. Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Invest Drugs 2004;13(6):643–52.

    Article  CAS  Google Scholar 

  22. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4(1):37–44.

    Article  CAS  PubMed  Google Scholar 

  23. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94(12):3184–9.

    CAS  PubMed  Google Scholar 

  24. Michaels AD, Klein A, Madden JA, et al. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003;107(21):2697–701.

    Article  CAS  PubMed  Google Scholar 

  25. Colucci WS, Elkayam U, Horton DP, et al., for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343(4):246–53.

    Article  CAS  PubMed  Google Scholar 

  26. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37(5):1221–7.

    Article  CAS  PubMed  Google Scholar 

  27. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemideinduced aldosterone activation in experimental heart failure. Circulation 2004;109(13):1680–5.

    Article  CAS  PubMed  Google Scholar 

  28. Aronson D, Burger AJ. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure. Am Heart J 2004;148(5):920–6.

    Article  Google Scholar 

  29. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–17.

    Article  CAS  PubMed  Google Scholar 

  30. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21.

    Article  CAS  PubMed  Google Scholar 

  31. Yancy CW. Treatment with B-type natriuretic peptide for chronic decompensated heart failure: insights learned from the follow up serial infusion of nesiritide (FUSION) trial. Heart Fail Rev 2004;9(3, special issue):209–16.

    CAS  PubMed  Google Scholar 

  32. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol 2002;90(4):435–8.

    Article  CAS  PubMed  Google Scholar 

  33. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76(1):91–6.

    Article  CAS  PubMed  Google Scholar 

  34. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998;274(1 pt 2):F63–72.

    CAS  PubMed  Google Scholar 

  35. Jensen KT, Eiskjaer H, Carstens J, et al. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond) 1999;96(1):5–15.

    Article  CAS  PubMed  Google Scholar 

  36. Akabane S, Matsushima Y, Matsuo H, et al. Effects of brain natriuretic peptide on renin secretion in normal and hypertonic saline-infused kidney. Eur J Pharmacol 1991;198(2–3):143–8.

    Article  CAS  PubMed  Google Scholar 

  37. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004;110(12):1620–5.

    Article  CAS  PubMed  Google Scholar 

  38. Elkayam U, Singh H, Akhter MW, et al. Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure (abstr 256). J Card Fail 2004;10(suppl 4):S88.

    Article  Google Scholar 

  39. Mills RM, LeJemtel TH, Horton DP, et al., on behalf of the Natrecor Study Group. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 1999;34(1):155–62.

    Article  CAS  PubMed  Google Scholar 

  40. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT Study. Am Heart J 2002;144(6):1102–8.

    Article  CAS  PubMed  Google Scholar 

  41. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287(12):1531–40.

    Article  Google Scholar 

  42. Peacock WF IV, Emerman CL, Silver MA, et al. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med 2005;23(3):327–31.

    Article  PubMed  Google Scholar 

  43. Peacock WF, Holland R, Gyarmathy R, et al. Observation unit treatment of heart failure with nesiritide: results from the PROACTION trial. J Emerg Med 2005;29(3):243–52.

    Article  PubMed  Google Scholar 

  44. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111(12):1487–91.

    Article  CAS  PubMed  Google Scholar 

  45. Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy 2004;24(5):697–702.

    Article  CAS  PubMed  Google Scholar 

  46. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147(2):331–8.

    Article  PubMed  Google Scholar 

  47. Abraham WT. Serum creatinine elevations in patients receiving nesiritide are related to starting dose (abstr 2789). Circulation 2005;112(17, suppl II):589.

    Google Scholar 

  48. Heywood JT. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine (abstr 240). J Card Fail 2005;11(6, suppl):S154.

    Google Scholar 

  49. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293(15):1900–5.

    Article  CAS  PubMed  Google Scholar 

  50. Gortney JS, Porter KB. Risk of death with nesiritide. JAMA 2005;294(8):897–8.

    Article  CAS  PubMed  Google Scholar 

  51. Burger AJ. Risk of death with nesiritide. JAMA 2005;294(8):897.

    Article  CAS  PubMed  Google Scholar 

  52. Abraham WT. Nesiritide does not increase 30-day or 6-month mortality risk. Circulation 2005;112(17, suppl II):676.

    Google Scholar 

  53. Arnold LM, Carroll NV, Oinonen M, Crouch MA. Mortality and length of hospital stay in patients receiving dobutamine, milrinone, or nesiritide for acute decompensated heart failure. J Card Fail 2004;10(suppl 4):S103.

    Article  Google Scholar 

  54. http://www.sciosinc.com/scios/pr_1118721302.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA

    Clyde W. Yancy MD, FACC, FAHA, FACP

Authors
  1. Clyde W. Yancy MD, FACC, FAHA, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Anesthesiology and Critical Care Medicine, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France

    Alexandre Mebazaa MD, PhD (Professor of Medicine) (Professor of Medicine)

  2. Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    Mihai Gheorghiade MD, FACC (Professor of Medicine and Surgery, Associate Chief, Division of Cardiology and Chief, Cardiology Clinical Service) (Professor of Medicine and Surgery, Associate Chief, Division of Cardiology and Chief, Cardiology Clinical Service)

  3. Department of Cardiology Centre d’Investigation Clinique (CIC), INSERM U-684, Centre Hospitalier Universitaire, University Henri Poincaré, Nancy, France

    Faiez M. Zannad MD, PhD, FESC (Professor of Medicine) (Professor of Medicine)

  4. Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Camden, NJ, USA

    Joseph E. Parrillo MD (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director) (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director)

  5. Cooper Heart Institute, Cooper University Hospital, Camden, NJ, USA

    Joseph E. Parrillo MD (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director) (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Yancy, C.W. (2008). Use of Nesiritide in the Management Algorithm of Acute Decompensated Heart Failure. In: Mebazaa, A., Gheorghiade, M., Zannad, F.M., Parrillo, J.E. (eds) Acute Heart Failure. Springer, London. https://doi.org/10.1007/978-1-84628-782-4_51

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-782-4_51

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-781-7

  • Online ISBN: 978-1-84628-782-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation